Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Myeloma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    602 result(s) found for: Myeloma. Displaying page 1 of 31.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-004282-31 Sponsor Protocol Number: V14-11056 Start Date*: 2017-03-15
    Sponsor Name:Vivolux AB
    Full Title: VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000987-31 Sponsor Protocol Number: 35RC17_8825_IMMUNO-MYELO Start Date*: 2021-04-23
    Sponsor Name:CHU Rennes
    Full Title: Immunomonitoring and multiple myeloma: impact of lenalidomide on immune checkpoint expression
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001292-11 Sponsor Protocol Number: NMSG 17/07 Start Date*: 2007-08-05
    Sponsor Name:Nordic Myeloma Study Group
    Full Title: Talidomid vs Velcade vid melfalanrefraktärt myelom
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003752-30 Sponsor Protocol Number: 088 Start Date*: 2008-11-27
    Sponsor Name:Merck & Co., Inc
    Full Title: Estudio internacional, multicéntrico, aleatorizado, doble ciego de Vorinostat (MK-0683) o placebo en combinación con bortezomib en pacientes con mieloma multiple An International, Multicenter, Ran...
    Medical condition: mieloma múltiple multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FR (Completed) AT (Completed) CZ (Completed) PT (Prematurely Ended) HU (Prematurely Ended) IT (Completed) BG (Prematurely Ended) GB (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003856-35 Sponsor Protocol Number: Uni-Koeln-3946 Start Date*: 2020-12-18
    Sponsor Name:University of Cologne
    Full Title: Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)
    Medical condition: multiple myeloma (untreated)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003599-39 Sponsor Protocol Number: AMD3100-3102-DE Start Date*: 2005-12-02
    Sponsor Name:AnorMED Corp.
    Full Title: A randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) plus placebo to mobilize and collect greater than or equal ...
    Medical condition: Mobilization of stem cells prior to autologous stem cell transplantation in patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022029-13 Sponsor Protocol Number: CBHQ880A2204 Start Date*: 2011-08-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with intravenous BHQ880, a fully human, anti-Dickkopf1 (DKK1) neutralizing antibody in previously un...
    Medical condition: Adults diagnosed with high-risk Smoldering Multiple Myeloma (SMM) and who have not received any previous antimyeloma treatment.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002675-41 Sponsor Protocol Number: CRAD001C2455 Start Date*: 2007-05-22
    Sponsor Name:Universitaetsklinikum Schleswig-Holstein
    Full Title: A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma
    Medical condition: Multiple Myeloma (Salmon-Durie stage II or III, Relapsed or refractory disease after failure of two or more treatment regimens)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001416-20 Sponsor Protocol Number: DSC/07/2357/29 Start Date*: 2009-05-19
    Sponsor Name:ITALFARMACO
    Full Title: Phase II High Pulse Dose Clinical Trial of Orally Administered ITF 2357 In Patients with Relapsed/Refractory Multiple Myeloma
    Medical condition: Patients with Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005425-30 Sponsor Protocol Number: AURA-6202-011 Start Date*: 2008-04-17
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression
    Medical condition: Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003926-10 Sponsor Protocol Number: CHUBX2017/32 Start Date*: 2019-02-13
    Sponsor Name:CHU de Bordeaux
    Full Title: Prospective comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the initial work-up of Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002557-38 Sponsor Protocol Number: Allo-MM-PostCy-Study Start Date*: 2018-02-13
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation for multiple myeloma. A phase II study.
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000054086 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001013-89 Sponsor Protocol Number: DAMTE Start Date*: 2018-08-28
    Sponsor Name:AZIENDA OSPEDALIERA "BIANCHI-MELACRINO-MORELLI"
    Full Title: Double ASCT in MM: phase III study comparing between melphalan based regimen vs a new regimen consisting of melphalan and thiotepa
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028566 Myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005103-32 Sponsor Protocol Number: H9S-MC-JDCG Start Date*: 2012-08-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 2 Study of LY2127399 in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma
    Medical condition: Previously Treated Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) GR (Completed) PL (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005638-56 Sponsor Protocol Number: 0805603 Start Date*: 2009-02-16
    Sponsor Name:CHU de TOULOUSE
    Full Title: Protocole IFM 2008 : Primo-traitement des patients de moins de 65 ans atteints de myélome
    Medical condition: Myelome, Myelome multiple
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028566 Myeloma LLT
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004580-19 Sponsor Protocol Number: REVIR Start Date*: 2008-10-14
    Sponsor Name:CHU DE POITIERS
    Full Title: PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID®) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FONCTION
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001175-29 Sponsor Protocol Number: MM-FOT-08 Start Date*: 2008-04-02
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Phase II trial evaluating fotemustine (Muphoran) treatment in patients with refractory or relapsing multiple myeloma
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004815-24 Sponsor Protocol Number: FM-MYEL-06-01 Start Date*: 2006-12-05
    Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
    Full Title: Bortezomib and dexamethasone treatment before donor lymphocyte infusions for myeloma patients progressing or relapsing after allogeneic transplantation of hematopoietic cells
    Medical condition: Myeloma patients progressing or relapsing after allogeneic transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003891-39 Sponsor Protocol Number: HOVON 76 MM Start Date*: 2007-05-22
    Sponsor Name:HOVON Foundation
    Full Title: Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005709-62 Sponsor Protocol Number: GEN503 Start Date*: 2012-08-01
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open label, International, Multicenter, Dose Escalating Phase 1/2 Trial Investigating the Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Re...
    Medical condition: Relapsed or Relapsed and Refractory Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:22:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA